Sarcopenia, Frailty Circle, and Treatment With SGLT2 Inhibitors

Journal of Diabetes Investigation- Australia

doi 10.1111/jdi.12966

Full Text

Abstract

Available in

Date

Authors

Publisher

Wiley

Related search

SGLT2 Inhibitors

2020English

Epidemiology of Sarcopenia and Frailty

2017English

Prevalence of Frailty, Cognitive Impairment, and Sarcopenia in Outpatients With Cardiometabolic Disease in a Frailty Clinic

BMC Geriatrics
GerontologyGeriatrics
2018English

SGLT2 Inhibitors: Mind the Gap

Chest
CardiologyCritical CareCardiovascular MedicineIntensive Care MedicinePulmonaryRespiratory Medicine
2016English

Nutritional Problematic Related to Frailty and Sarcopenia in Older

Nutricion Hospitalaria
MedicineNutritionDietetics
2019English

Healthy Ageing, Appetite, Frailty and Sarcopenia: A Brief Overview

European Journal of Integrative Medicine
Alternative MedicineComplementary
2019English

Effects of SGLT2 Inhibitors in the Treatment of a Population With Type 2 Diabetes Mellitus

Endocrine Abstracts
2016English

The Frailty Phenotype and Sarcopenia: Similar but Not the Same

Aging Medicine
AgingGerontologyGeriatrics
2019English

Is Cancer Incidence Modified by SGLT2 Inhibitors?

Diabetes Mellitus
Internal MedicineEndocrinologyMetabolismDiabetes
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy